Aardvark Therapeutics
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Aardvark Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Aardvark Therapeutics: 6 sponsored US clinical trials, none currently recruiting.
Aardvark Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 2 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prader-Willi Syndrome, with 1 trials.
Upper-quartile sponsor footprint
Aardvark Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
6 total, page 1 of 1
ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial
NCT06828861
A Study to Evaluate ARD-501 in Patients With Autism Spectrum Disorder
NCT06126653
The Hunger Elimination or Reduction Objective (HERO ) Open -Label Extension (OLE) Trial
NCT07197034
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
NCT05153434
Study to Evaluate ARD-101 in Adults Receiving Bariatric Surgery
NCT05215847
Study to Evaluate ARD-101 in Adults With Obesity
NCT05121441
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 2 |
Therapeutic Areas
How the Aardvark Therapeutics early-phase archive is shaped
6 indexed studies, none listed as recruiting (0% open); 4 completed (67%).
Phase mix: 2 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Prader-Willi Syndrome (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Aardvark Therapeutics: archived-pipeline peers nationwide
Peers matched on 6 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Aardvark Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 archived trials
- 23andMe · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
- Abivax S.A. · 6 trials · 33% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
Related
What to do with this Aardvark Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Aardvark Therapeutics or any single study.
- None of Aardvark Therapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Prader-Willi Syndrome is the condition Aardvark Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prader-Willi Syndrome trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aardvark Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.